Anthony Mato, MD

Articles

Dr. Mato on the Potential Use of Noncovalent BTK Inhibitors in CLL

March 2nd 2023

Anthony Mato, MD, MSCE, discusses recent data on the emerging class of noncovalent BTK inhibitors in chronic lymphocytic leukemia and their potential advantage over currently approved covalent BTK inhibitors.

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

January 6th 2023

Dr Anthony Mato reviews the extended follow-up results from the phase 1/2 BRUIN Study that evaluated the use of pirtobrutinib in patients with lymphoma.

Rapid Readout: Pirtobrutinib, A Highly Selective, Noncovalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study

January 14th 2022

Anthony Mato, MD, discusses updated efficacy and safety results from the phase 1/2 BRUIN study of the noncovalent BTK inhibitor, pirtobrutinib, in patients with previously treated CLL/SLL that was presented at the American Society of Hematology 2021 Annual Meeting.

MRD Testing in CLL

November 24th 2021

Circumstances for which MRD testing may be considered for patients with chronic lymphocytic leukemia.

Future Directions Treating CLL With Novel Therapy-Based Regimens

November 15th 2021

Considerations for using novel fixed-duration regimens and triplet therapy to treat patients with chronic lymphocytic leukemia.

Dr. Mato on the Potential for Early Utilization of CAR T-Cell Therapy in CLL

November 8th 2021

Anthony Mato, MD, MSCE, discusses the potential utilization of CAR T-cell therapy in earlier lines of therapy in chronic lymphocytic leukemia.

Dr. Mato Discusses Advances in the Treatment of Patients With CLL

November 4th 2021

Anthony Mato, MD, MSCE, discusses recent advances made in the treatment of patients with chronic lymphocytic leukemia.

Dr. Mato on Managing Side Effects With Ibrutinib/Idelalisib in CLL

August 24th 2016

Anthony Mato, MD, director of the Chronic Lymphocytic Leukemia Program, University of Pennsylvania, discusses how oncologists can manage adverse events associated with ibrutinib (Imbruvica) and idelalisib (Zydelig) for the treatment of patients with chronic lymphocytic leukemia (CLL).